Tue, June 6, 2023
Mon, June 5, 2023
Sat, June 3, 2023
Fri, June 2, 2023
Thu, June 1, 2023

Matthew Biegler Initiated (ACRV) at Buy and Held Target at $25 on, Jun 2nd, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. t-buy-and-held-target-at-25-on-jun-2nd-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Biegler of Oppenheimer, Initiated "Acrivon Therapeutics, Inc." (ACRV) at Buy and Held Target at $25 on, Jun 2nd, 2023.

Matthew has made no other calls on ACRV in the last 4 months.



There are 2 other peers that have a rating on ACRV. Out of the 2 peers that are also analyzing ACRV, 0 agree with Matthew's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Matthew


  • Etzer Darout of "BMO Capital" Initiated at Buy and Held Target at $25 on, Monday, May 8th, 2023
  • Emily Bodnar of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $24 on, Tuesday, May 2nd, 2023

Publication Contributing Sources